The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for  Chronic Hepatitis C Virus Infection – MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...

The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. “HCV co-infection remains a major cause

Norwegian hepatitis C patients wait for treatment due to medicine monopoly: report

Norwegian hepatitis C patients are waiting longer than they should for medical treatment due in part to a monopoly on its supply, according to a report. Between 15,000 and 20,000 Norwegians live with the chronic condition, which is treated with a 12-week course of medicine. The cost of a 12-week course of the Epclusa medicine in Norway is 540,000 kroner (57,000 euros), according to the Klassekampen newspaper. American pharmaceutical company Gilead S

The Week in Review: June 2 – June 9, 2017

Friday, June 9, 2017 News Recap Somebody Pinch Me This week saw the release of a report from the Cochrane Collaboration which concluded not only that DAAs were ineffective but that they might also be bad for you and not even cure HCV.  The news item was picked up by various media outlets and was hard to miss (No valid evidence $40,000 miracle drug cures hepatitis C – study).  Thankfully other researchers from around the world jumped in on this poor ...

WHO recommends Epclusa, a Hepatitis C Combined Therapy in Just One Pill

A combined treatment for hepatitis C based on sofosbuvir and velpatasvir (brand name Epclusa) is among the additions to the World Health Organization (WHO) Model List of Essential Medicines (EML) for 2017. Velpatasvir is an antiviral drug that inhibits a viral protein called NS5A. This drug prevents the replication of the virus and the assembly of new virus particles. Sofosbuvir, which already was included in the previous EML, targets another protein in t

The Week in Review: April 28, 2017 – May 5, 2017

Friday, May 5, 2017 News Recap Canada Great news from Nova Scotia: Expanded access to and coverage for treatment of chronic hepatitis C is now available under the provincial Pharmacare plan, similar to the new arrangements in BC, Alberta, Ontario, Saskatchewan and Quebec.  The drugs covered are: Epclusa, Daklinza, Sunvepra, Zepatier, Harvoni and Sovaldi. You can read the Nova Scotia Pharmacare Formulary Updates here (Nova Scotia Lists EPCLUSA™ on P...

Nova Scotia: New drug will help with hepatitis C treatment

Nova Scotians will soon have access to a new drug to help treat hepatitis C. Nova Scotia’s Department of Health and Wellness announced Monday the province will provide public access to EPCLUSA tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C. With this drug, patients take one tablet daily for 12 weeks, provided they are adult patients without cirrhosis or with compensat

Alberta expands drug coverage for hepatitis C patients

“Effective April 2017, Alberta Health has agreed to pay for several new therapies for the treatment of hepatitis C, the most important of which is a medicine called Epclusa, which contains two anti-viral drugs,” said Stephen Shafran, a professor of medicine at the University of Alberta. Epclusa, a drug for hep C with a near 100 per cent cure rate, is now going to be covered by Alberta Health. “This should give people hope that they can be cured,” Shafr